pteridines has been researched along with Melanoma in 12 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In two groups of patients with checked diagnoses of the malignant melanoma and Hodgkin's disease we followed changes of the renal excretion of two major pterines, neopterine and biopterine." | 7.67 | Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease. ( Andrysek, O; Cernovská, I; Vasícková, M; Zitko, M, 1986) |
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 6.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| "Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal." | 5.38 | In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012) |
| " We used an exploratory study into plasma concentrations of large neutral amino acids, 5-hydroxyindolacetic acid (5-HIAA), total biopterin (BIOP) and neopterin (NEOP) in 40 high-risk melanoma patients." | 5.11 | Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. ( Bannink, M; Eggermont, AM; Fekkes, D; Kruit, WH; Mulder, PG; Stoter, G; Van Gool, AR; van Ojik, HH, 2004) |
| "The effect was studied of a number of synthetic indoleamines, pteridines, beta-carbolines, of AVT and of crude extracts from rat and ovine pineal glands on human melanoma cells in vitro." | 3.67 | Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances. ( Bartsch, C; Bartsch, H; Ebels, I; Flehmig, B; Noteborn, HP; Salemink, CA, 1987) |
| "In two groups of patients with checked diagnoses of the malignant melanoma and Hodgkin's disease we followed changes of the renal excretion of two major pterines, neopterine and biopterine." | 3.67 | Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease. ( Andrysek, O; Cernovská, I; Vasícková, M; Zitko, M, 1986) |
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 2.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| "Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal." | 1.38 | In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Theodosakis, N | 1 |
| Micevic, G | 1 |
| Langdon, CG | 1 |
| Ventura, A | 1 |
| Means, R | 1 |
| Stern, DF | 1 |
| Bosenberg, MW | 1 |
| Cholewa, BD | 2 |
| Pellitteri-Hahn, MC | 1 |
| Scarlett, CO | 1 |
| Ahmad, N | 2 |
| Ndiaye, MA | 1 |
| Huang, W | 1 |
| Liu, X | 1 |
| Schöffski, P | 1 |
| Blay, JY | 1 |
| De Greve, J | 1 |
| Brain, E | 1 |
| Machiels, JP | 1 |
| Soria, JC | 1 |
| Sleijfer, S | 1 |
| Wolter, P | 1 |
| Ray-Coquard, I | 1 |
| Fontaine, C | 1 |
| Munzert, G | 1 |
| Fritsch, H | 1 |
| Hanft, G | 1 |
| Aerts, C | 1 |
| Rapion, J | 1 |
| Allgeier, A | 1 |
| Bogaerts, J | 1 |
| Lacombe, D | 1 |
| Mohammad, KS | 1 |
| Javelaud, D | 1 |
| Fournier, PG | 1 |
| Niewolna, M | 1 |
| McKenna, CR | 1 |
| Peng, XH | 1 |
| Duong, V | 1 |
| Dunn, LK | 1 |
| Mauviel, A | 1 |
| Guise, TA | 1 |
| de Oliveira, JC | 1 |
| Brassesco, MS | 1 |
| Pezuk, JA | 1 |
| Morales, AG | 1 |
| Valera, ET | 1 |
| Montaldi, AP | 1 |
| Sakamoto-Hojo, ET | 1 |
| Scrideli, CA | 1 |
| Tone, LG | 1 |
| Kapoor, S | 1 |
| Van Gool, AR | 1 |
| van Ojik, HH | 1 |
| Kruit, WH | 1 |
| Bannink, M | 1 |
| Mulder, PG | 1 |
| Eggermont, AM | 1 |
| Stoter, G | 1 |
| Fekkes, D | 1 |
| Gregory, CR | 1 |
| Harmon, BG | 1 |
| Latimer, KS | 1 |
| Hafner, S | 1 |
| Campagnoli, RP | 1 |
| McManamon, RM | 1 |
| Steffens, WL | 1 |
| Bartsch, H | 1 |
| Bartsch, C | 1 |
| Noteborn, HP | 1 |
| Flehmig, B | 1 |
| Ebels, I | 1 |
| Salemink, CA | 1 |
| Zitko, M | 1 |
| Andrysek, O | 1 |
| Cernovská, I | 1 |
| Vasícková, M | 1 |
| Pomerantz, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)[NCT00526149] | Phase 2 | 76 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pteridines and Melanoma
| Article | Year |
|---|---|
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Feasibility Studies; Female; Head and Neck Neo | 2010 |
Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.
Topics: Adult; Aged; Amino Acids; Biopterins; Drug Administration Schedule; Female; Humans; Hydroxyindoleace | 2004 |
10 other studies available for pteridines and Melanoma
| Article | Year |
|---|---|
p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; MAP Kinase Kinas | 2017 |
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Heterogeneous-Nuclear Ribonucleoprotein Group C; Humans; Mela | 2014 |
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cell Pr | 2017 |
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.
Topics: Animals; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progressio | 2011 |
In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progressio | 2012 |
New inhibitors of Polo-like kinase 1 function and their emerging role in attenuating tumor growth in systemic malignancies.
Topics: Cell Cycle Proteins; Humans; Melanoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pt | 2012 |
Malignant chromatophoroma in a canebrake rattlesnake (Crotalus horridus atricaudatus).
Topics: Animals; Chromatography, Paper; Chromatophores; Crotalus; Female; Histocytochemistry; Immunohistoche | 1997 |
Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances.
Topics: Animals; Brain; Carbolines; Cell Count; Cell Division; Cell Line; Growth Inhibitors; Humans; Indoles | 1987 |
Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease.
Topics: Biopterins; Chromatography, Thin Layer; Female; Hodgkin Disease; Humans; Kidney; Male; Melanoma; Neo | 1986 |
Tyrosine hydroxylation catalyzed by mammalian tyrosinase: an improved method of assay.
Topics: Animals; Cricetinae; Dihydroxyphenylalanine; In Vitro Techniques; Kinetics; Melanoma; Neoplasms, Exp | 1964 |